| Dr Lindsey Kay Collins, MD | |
|
619 Ne 13th St, Oklahoma City, OK 73104-5001 | |
| (405) 271-4662 | |
| Not Available |
| Full Name | Dr Lindsey Kay Collins |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 12 Years |
| Location | 619 Ne 13th St, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316200413 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | LL34736 (South Carolina) | Secondary |
| 207N00000X | Dermatology | 33139 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| O U Medical Center | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ou Health Partners Inc | 5991105876 | 779 |
News Archive
BioAmber, Inc. has been awarded a 2011 Presidential Green Chemistry Challenge Award, presented by the Environmental Protection Agency (EPA) and the American Chemical Society (ACS). The Award promotes technology that provides substantial environmental benefits using green chemistry. BioAmber's platform was recognized as the leading technology in the field of succinic acid.
Up to 70 per cent of Victorians with suspected hepatitis C may not have received follow-up testing, putting them at risk of chronic liver disease and even cancer, University of Melbourne researchers say.
As the COVID-19 pandemic and its far-reaching implications continue to unfold globally and disrupt our normal way of life, scientists and researchers are racing to find an appropriate vaccine or therapeutic drug. This process involves understanding how the virus interacts with the host cell, the dynamics of the host immune response, and the eventual outcome.
The London-based LouLou Foundation and the Orphan Disease Center of the Perelman School of Medicine at the University of Pennsylvania have established a Program of Excellence to develop effective treatments for children with CDKL5, a rare X-chromosome-linked genetic disorder that causes severe neuro-developmental impairment and early-onset, difficult-to-control seizures.
Neuroblastoma is one of the most common and lethal types of childhood cancers. In a paper published online today in OncoTarget, a researcher at the University of Texas Health Science Center at San Antonio unveils the important role of microRNAs in regulating neuroblastoma development, pointing to new therapeutic possibilities.
› Verified 7 days ago
| Entity Name | Board Of Regents Of The University Of Oklahoma - Ou Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801869250 PECOS PAC ID: 2860304334 Enrollment ID: O20031103000607 |
News Archive
BioAmber, Inc. has been awarded a 2011 Presidential Green Chemistry Challenge Award, presented by the Environmental Protection Agency (EPA) and the American Chemical Society (ACS). The Award promotes technology that provides substantial environmental benefits using green chemistry. BioAmber's platform was recognized as the leading technology in the field of succinic acid.
Up to 70 per cent of Victorians with suspected hepatitis C may not have received follow-up testing, putting them at risk of chronic liver disease and even cancer, University of Melbourne researchers say.
As the COVID-19 pandemic and its far-reaching implications continue to unfold globally and disrupt our normal way of life, scientists and researchers are racing to find an appropriate vaccine or therapeutic drug. This process involves understanding how the virus interacts with the host cell, the dynamics of the host immune response, and the eventual outcome.
The London-based LouLou Foundation and the Orphan Disease Center of the Perelman School of Medicine at the University of Pennsylvania have established a Program of Excellence to develop effective treatments for children with CDKL5, a rare X-chromosome-linked genetic disorder that causes severe neuro-developmental impairment and early-onset, difficult-to-control seizures.
Neuroblastoma is one of the most common and lethal types of childhood cancers. In a paper published online today in OncoTarget, a researcher at the University of Texas Health Science Center at San Antonio unveils the important role of microRNAs in regulating neuroblastoma development, pointing to new therapeutic possibilities.
› Verified 7 days ago
| Entity Name | Ou Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528642642 PECOS PAC ID: 5991105876 Enrollment ID: O20210615000618 |
News Archive
BioAmber, Inc. has been awarded a 2011 Presidential Green Chemistry Challenge Award, presented by the Environmental Protection Agency (EPA) and the American Chemical Society (ACS). The Award promotes technology that provides substantial environmental benefits using green chemistry. BioAmber's platform was recognized as the leading technology in the field of succinic acid.
Up to 70 per cent of Victorians with suspected hepatitis C may not have received follow-up testing, putting them at risk of chronic liver disease and even cancer, University of Melbourne researchers say.
As the COVID-19 pandemic and its far-reaching implications continue to unfold globally and disrupt our normal way of life, scientists and researchers are racing to find an appropriate vaccine or therapeutic drug. This process involves understanding how the virus interacts with the host cell, the dynamics of the host immune response, and the eventual outcome.
The London-based LouLou Foundation and the Orphan Disease Center of the Perelman School of Medicine at the University of Pennsylvania have established a Program of Excellence to develop effective treatments for children with CDKL5, a rare X-chromosome-linked genetic disorder that causes severe neuro-developmental impairment and early-onset, difficult-to-control seizures.
Neuroblastoma is one of the most common and lethal types of childhood cancers. In a paper published online today in OncoTarget, a researcher at the University of Texas Health Science Center at San Antonio unveils the important role of microRNAs in regulating neuroblastoma development, pointing to new therapeutic possibilities.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lindsey Kay Collins, MD 619 Ne 13th St, Oklahoma City, OK 73104-5001 Ph: (405) 271-4662 | Dr Lindsey Kay Collins, MD 619 Ne 13th St, Oklahoma City, OK 73104-5001 Ph: (405) 271-4662 |
News Archive
BioAmber, Inc. has been awarded a 2011 Presidential Green Chemistry Challenge Award, presented by the Environmental Protection Agency (EPA) and the American Chemical Society (ACS). The Award promotes technology that provides substantial environmental benefits using green chemistry. BioAmber's platform was recognized as the leading technology in the field of succinic acid.
Up to 70 per cent of Victorians with suspected hepatitis C may not have received follow-up testing, putting them at risk of chronic liver disease and even cancer, University of Melbourne researchers say.
As the COVID-19 pandemic and its far-reaching implications continue to unfold globally and disrupt our normal way of life, scientists and researchers are racing to find an appropriate vaccine or therapeutic drug. This process involves understanding how the virus interacts with the host cell, the dynamics of the host immune response, and the eventual outcome.
The London-based LouLou Foundation and the Orphan Disease Center of the Perelman School of Medicine at the University of Pennsylvania have established a Program of Excellence to develop effective treatments for children with CDKL5, a rare X-chromosome-linked genetic disorder that causes severe neuro-developmental impairment and early-onset, difficult-to-control seizures.
Neuroblastoma is one of the most common and lethal types of childhood cancers. In a paper published online today in OncoTarget, a researcher at the University of Texas Health Science Center at San Antonio unveils the important role of microRNAs in regulating neuroblastoma development, pointing to new therapeutic possibilities.
› Verified 7 days ago
Jason Matthew Hirshburg, M.D. PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: University Of Oklahoma Hsc - Dermatology, 619 N.e. 13th St, Oklahoma City, OK 73104 Phone: 405-271-4662 Fax: 405-271-4662 | |
Raymond L Cornelison, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3727 Nw 63rd St Ste 205, Oklahoma City, OK 73116 Phone: 405-608-4494 Fax: 405-608-4504 | |
Dr. Carlos Andres Garcia, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4805 S Western Ave, Oklahoma City, OK 73109 Phone: 405-636-1506 Fax: 405-636-1511 | |
Mark Stover Sullivan, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3366 Nw Expressway, Suite 720, Oklahoma City, OK 73112 Phone: 405-947-0676 Fax: 405-945-4876 | |
Dr. Brandon Rhinehart, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13100 N Western, Ste 301, Oklahoma City, OK 73114 Phone: 405-947-6647 Fax: 405-948-6647 | |
Mark A Dawkins, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13174 N Macarthur Blvd, Oklahoma City, OK 73142 Phone: 405-721-5555 Fax: 405-470-7093 | |
James W Taira, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1211 N Shartel Ave, Suite 202, Oklahoma City, OK 73103 Phone: 405-235-7546 |